PortalPublikationenSilibinin protects mice from T cell-dependent liver injury.

Silibinin protects mice from T cell-dependent liver injury.

Standard

Silibinin protects mice from T cell-dependent liver injury. / Schümann, Jens; Prockl, Jennifer; Kiemer, Alexandra K; Vollmar, Angelika M; Bang, Renate; Tiegs, Gisa.

in: J HEPATOL, Jahrgang 39, Nr. 3, 3, 2003, S. 333-340.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schümann, J, Prockl, J, Kiemer, AK, Vollmar, AM, Bang, R & Tiegs, G 2003, 'Silibinin protects mice from T cell-dependent liver injury.', J HEPATOL, Jg. 39, Nr. 3, 3, S. 333-340. <http://www.ncbi.nlm.nih.gov/pubmed/12927918?dopt=Citation>

APA

Schümann, J., Prockl, J., Kiemer, A. K., Vollmar, A. M., Bang, R., & Tiegs, G. (2003). Silibinin protects mice from T cell-dependent liver injury. J HEPATOL, 39(3), 333-340. [3]. http://www.ncbi.nlm.nih.gov/pubmed/12927918?dopt=Citation

Vancouver

Schümann J, Prockl J, Kiemer AK, Vollmar AM, Bang R, Tiegs G. Silibinin protects mice from T cell-dependent liver injury. J HEPATOL. 2003;39(3):333-340. 3.

Bibtex

@article{ecb39675fd0348129668859338bed9cf,
title = "Silibinin protects mice from T cell-dependent liver injury.",
abstract = "Silibinin is the major pharmacologically active compound of the Silybum marianum fruit extract silymarin. Its well-known hepatoprotective activities are mostly explained by antioxidative properties, inhibition of phosphatidylcholine synthesis or stimulation of hepatic RNA and protein synthesis. Here, we characterized the hepatoprotective potential of silibinin as an immune-response modifier in T cell-dependent hepatitis in vivo.",
keywords = "Animals, Male, Cells, Cultured, Mice, Mice, Inbred BALB C, NF-kappa B/metabolism, Recombinant Proteins, Drug-Induced Liver Injury, Concanavalin A/pharmacology, Cytokines/genetics/metabolism, *Cytoprotection, Enzyme Induction/drug effects, Galactosamine, Leukocytes/drug effects/metabolism, Liver/*drug effects/metabolism, Liver Diseases/*etiology/*prevention & control, Nitric Oxide Synthase/biosynthesis, Nitric Oxide Synthase Type II, RNA, Messenger/biosynthesis, Silymarin/*pharmacology, *T-Lymphocytes, Tumor Necrosis Factor-alpha, Animals, Male, Cells, Cultured, Mice, Mice, Inbred BALB C, NF-kappa B/metabolism, Recombinant Proteins, Drug-Induced Liver Injury, Concanavalin A/pharmacology, Cytokines/genetics/metabolism, *Cytoprotection, Enzyme Induction/drug effects, Galactosamine, Leukocytes/drug effects/metabolism, Liver/*drug effects/metabolism, Liver Diseases/*etiology/*prevention & control, Nitric Oxide Synthase/biosynthesis, Nitric Oxide Synthase Type II, RNA, Messenger/biosynthesis, Silymarin/*pharmacology, *T-Lymphocytes, Tumor Necrosis Factor-alpha",
author = "Jens Sch{\"u}mann and Jennifer Prockl and Kiemer, {Alexandra K} and Vollmar, {Angelika M} and Renate Bang and Gisa Tiegs",
year = "2003",
language = "English",
volume = "39",
pages = "333--340",
journal = "J HEPATOL",
issn = "0168-8278",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - Silibinin protects mice from T cell-dependent liver injury.

AU - Schümann, Jens

AU - Prockl, Jennifer

AU - Kiemer, Alexandra K

AU - Vollmar, Angelika M

AU - Bang, Renate

AU - Tiegs, Gisa

PY - 2003

Y1 - 2003

N2 - Silibinin is the major pharmacologically active compound of the Silybum marianum fruit extract silymarin. Its well-known hepatoprotective activities are mostly explained by antioxidative properties, inhibition of phosphatidylcholine synthesis or stimulation of hepatic RNA and protein synthesis. Here, we characterized the hepatoprotective potential of silibinin as an immune-response modifier in T cell-dependent hepatitis in vivo.

AB - Silibinin is the major pharmacologically active compound of the Silybum marianum fruit extract silymarin. Its well-known hepatoprotective activities are mostly explained by antioxidative properties, inhibition of phosphatidylcholine synthesis or stimulation of hepatic RNA and protein synthesis. Here, we characterized the hepatoprotective potential of silibinin as an immune-response modifier in T cell-dependent hepatitis in vivo.

KW - Animals

KW - Male

KW - Cells, Cultured

KW - Mice

KW - Mice, Inbred BALB C

KW - NF-kappa B/metabolism

KW - Recombinant Proteins

KW - Drug-Induced Liver Injury

KW - Concanavalin A/pharmacology

KW - Cytokines/genetics/metabolism

KW - Cytoprotection

KW - Enzyme Induction/drug effects

KW - Galactosamine

KW - Leukocytes/drug effects/metabolism

KW - Liver/drug effects/metabolism

KW - Liver Diseases/etiology/prevention & control

KW - Nitric Oxide Synthase/biosynthesis

KW - Nitric Oxide Synthase Type II

KW - RNA, Messenger/biosynthesis

KW - Silymarin/pharmacology

KW - T-Lymphocytes

KW - Tumor Necrosis Factor-alpha

KW - Animals

KW - Male

KW - Cells, Cultured

KW - Mice

KW - Mice, Inbred BALB C

KW - NF-kappa B/metabolism

KW - Recombinant Proteins

KW - Drug-Induced Liver Injury

KW - Concanavalin A/pharmacology

KW - Cytokines/genetics/metabolism

KW - Cytoprotection

KW - Enzyme Induction/drug effects

KW - Galactosamine

KW - Leukocytes/drug effects/metabolism

KW - Liver/drug effects/metabolism

KW - Liver Diseases/etiology/prevention & control

KW - Nitric Oxide Synthase/biosynthesis

KW - Nitric Oxide Synthase Type II

KW - RNA, Messenger/biosynthesis

KW - Silymarin/pharmacology

KW - T-Lymphocytes

KW - Tumor Necrosis Factor-alpha

M3 - SCORING: Journal article

VL - 39

SP - 333

EP - 340

JO - J HEPATOL

JF - J HEPATOL

SN - 0168-8278

IS - 3

M1 - 3

ER -